Linkedin Youtube
Launch Digital Edition

Webinars and Commercial Conversations — Register Now

Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.

Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Marketplace Directory

FDA approves Myriad MyChoice CDx

January 2020—The FDA has approved Myriad Genetics’ MyChoice CDx for use as a companion diagnostic to identify women with advanced ovarian cancer who are candidates for Zejula (niraparib) in the late-line treatment setting. The FDA also approved the expanded use of Zejula (GlaxoSmithKline) for the treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer patients who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency.

ChromaCode launches multidrug resistance assay

January 2020—ChromaCode has launched the HDPCR Multi-Drug Resistance (MDR) Panel, a highly multiplexed real-time PCR assay. The panel detects nine of the most common causes of Gram-negative multidrug resistance and toxigenic Clostridium difficile in a 96-well format. Key features of the panel, the company reports, include seamless integration onto common qPCR instrumentation, scalable throughput, and streamlined data analysis, management, and test customization with ChromaCode Cloud software. The MDR panel is for research use only.

Qiagen expands immuno-oncology portfolio

January 2020—Qiagen announced a series of agreements that expand its immuno-oncology assets for future commercialization of novel companion diagnostics, in particular based on next-generation sequencing technology. The agreements include a collaboration with Tokyo-based Repertoire Genesis that will provide access to novel technologies for the development of T-cell/B-cell receptor repertoire assays for use on NGS systems.

Beckman Coulter acquires Cytobank

January 2020—Beckman Coulter Life Sciences announced its acquisition of Cytobank, a privately held, single-cell data analysis, software-as-a-service company based in Santa Clara, Calif.

Quansys Q-Plex technology

December 2019—Quansys Biosciences (Logan, Utah) announced that its Q-Plex technology has been selected as a featured innovation at the Geneva Health Forum in Switzerland, March 24–26, 2020.

DiaSorin VZV swab test gets CE mark

December 2019—DiaSorin Molecular received the CE mark for its Simplexa VZV Swab Direct assay. The molecular diagnostic test enables the direct detection of varicella-zoster virus DNA from cutaneous and mucocutaneous swab specimens.

Menarini launches MSBiosuite

December 2019—Menarini Silicon Biosystems launched MSBiosuite, a cloud-based solution that automates next-generation-sequencing data analysis for liquid biopsy and formalin-fixed, paraffin-embedded workflows. The solution, developed in partnership with BlueBee, provides NGS data processing, analysis, interpretation, and reporting for users of Menarini NGS library preparation kits. A clinical interpretation report is available optionally with the Ampli1 and DEPArray OncoSeek pipelines.

Nova Biomedical introduces electrolyte analyzer

December 2019—Nova Biomedical announced the release of its Stat Profile Prime ES Comp Plus. The analyzer offers a complete electrolyte profile, including ionized magnesium, and optional serial batch testing on whole blood, serum, or plasma.

CellaVision buys RAL Diagnostics

December 2019—On Oct. 1, CellaVision completed the acquisition of RAL Diagnostics (Martillac, France). RAL develops and sells products for sample preparation in hematology, microbiology, cytology, and pathology.

Roche launches Cobas EBV, BKV tests

December 2019—Roche announced the commercial availability of the Cobas EBV (Epstein-Barr virus) and Cobas BKV (BK virus) tests for use on the Cobas 6800/8800 systems in countries accepting the CE mark. The tests are used to assess if transplant patients are at risk of developing disease by these pathogens, which can contribute to organ rejection.

MARKETPLACE

TRENDING